Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Hum Reprod. 2010 Aug;25(8):2068-83. doi: 10.1093/humrep/deq137. Epub 2010 Jun 23.
Novel therapeutic approaches for endometriosis based on molecular strategies may prove to be useful. Conditionally replicative adenoviruses (CRAds) are designed to exploit key differences between target and normal cells. The wild-type adenovirus (Adwt) promoter can be replaced by tissue-specific promoters, allowing viral replication only in target cells. Viral infectivity can be enhanced by altering Ad tropism via fiber modification. We investigated whether CRAds can be used to target endometriosis and determined the most efficient transcriptional- and transductional-targeting strategy.
An in vitro study was carried out using human endometriotic cell lines, 11Z (epithelial) and 22B (stromal), normal human ovarian surface epithelial cell line (NOSE006) and primary human endometriosis cells. A total of 9 promoters and 12 Ad tropism modifications were screened by means of a luciferase reporter assay. From this screening data, three CRAds (CRAd-S-pK7, CRAd-S-RGD, CRAd-S-F5/3sigma1, all incorporating the survivin promoter but with different fiber modifications) were selected to perform experiments using Adwt and a replication-deficient virus as controls. CRAds were constructed using a plasmid recombination system. Viral-binding capacity, rates of entry and DNA replication were evaluated by quantitative real-time PCR of viral genome copy. Cell-killing effects were determined by crystal violet staining and a cell viability assay for different concentrations of viral particles per cell.
Comparison of promoters demonstrated that the survivin promoter exhibited the highest induction in both endometriotic cell lines. Among the fiber-modified viruses, the polylysine modification (pK7) showed the best infection enhancement. CRAd-S-pK7 was validated as the optimal CRAd to target endometriosis in terms of binding ability, entry kinetics, DNA replication and cell-killing effect. CRAd-S-pK7 also exhibited a high level of DNA replication in primary endometriosis cells.
CRAd-S-pK7 has the best infection and cell-killing effect in the context of endometriosis. It could prove to be a useful novel method to target refractory cases of endometriosis.
基于分子策略的子宫内膜异位症新疗法可能被证明是有用的。条件复制型腺病毒(CRAds)旨在利用靶细胞和正常细胞之间的关键差异。野生型腺病毒(Adwt)启动子可被组织特异性启动子取代,仅允许病毒在靶细胞中复制。通过纤维修饰改变 Ad 嗜性可以增强病毒感染力。我们研究了 CRAds 是否可用于靶向子宫内膜异位症,并确定了最有效的转录和转导靶向策略。
采用体外实验方法,使用人子宫内膜异位症细胞系 11Z(上皮)和 22B(基质)、正常人卵巢表面上皮细胞系(NOSE006)和原代人子宫内膜异位症细胞进行研究。通过荧光素酶报告基因检测筛选了 9 个启动子和 12 种 Ad 嗜性修饰。根据筛选数据,选择了三种 CRAds(CRAd-S-pK7、CRAd-S-RGD、CRAd-S-F5/3sigma1,均含有生存素启动子,但纤维修饰不同),并与 Adwt 和复制缺陷型病毒作为对照进行实验。CRAds 采用质粒重组系统构建。通过定量实时 PCR 检测病毒基因组拷贝数来评估病毒结合能力、进入和 DNA 复制率。通过结晶紫染色和细胞活力测定不同浓度病毒颗粒对细胞的杀伤作用来确定细胞杀伤效果。
启动子比较显示,生存素启动子在两种子宫内膜异位症细胞系中均表现出最高的诱导作用。在纤维修饰的病毒中,多聚赖氨酸修饰(pK7)显示出最佳的感染增强作用。在结合能力、进入动力学、DNA 复制和细胞杀伤效果方面,CRAd-S-pK7 被验证为靶向子宫内膜异位症的最佳 CRAd。CRAd-S-pK7 还在原代子宫内膜异位症细胞中表现出高水平的 DNA 复制。
CRAd-S-pK7 在子宫内膜异位症中具有最佳的感染和细胞杀伤作用。它可能成为靶向难治性子宫内膜异位症的一种有用的新方法。